Skip to Content

Join the 'Berinert' group to help and get support from people like you.

Berinert News

CSL Behring Receives FDA Approval of Expanded Label on Berinert for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema

Posted 4 Jan 2012 by Drugs.com

Patients with rare, sometimes life-threatening condition can now treat themselves at home at the first sign of acute facial, abdominal or laryngeal swelling attacks KING OF PRUSSIA, Pa., Jan. 3, 2012 /PRNewswire/ – CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for self-administration of Berinert ®, C1 Esterase Inhibitor (Human),  a pasteurized, nanofiltered therapy indicated for the treatment of acute attacks of hereditary angioedema (HAE), a rare and potentially fatal genetic disorder. With appropriate training from a physician, patients can now self-administer Berinert by intravenous infusion. As part of the label expansion, Berinert is now also indicated to treat life-threatening laryngeal HAE attacks, as well as facial and abdominal attacks. "Once the early signs of an HAE attack begin to emerge, any delay in starting t ... Read more

Related support groups: Hereditary Angioedema, Berinert, C1 Inhibitor (Human)

Ask a Question

Further Information

Related Condition Support Groups

Hereditary Angioedema

Berinert Patient Information at Drugs.com